MTHFR 677C→T polymorphism and risk of coronary heart disease: A meta-analysis

JAMA

Volumn 288, Issue 16, 2002, Pages 2023-2031

  Klerk, Mariska ^a   Verhoef, Petra ^a   Clarke, Robert ^b   Blom, Henk J ^c   Kok, Frans J ^a   Schouten, Evert G ^a   Abbate, R ^d   Marcucci, R ^d   Samani, N J ^e   Anderson, J L ^f   Zebrack, J S ^f   Ardissino, D ^g   Merlini, F M ^g   Bonomi, Angelo Bianchi ^g   Van Bockxmeer, F M ^h   Brownrigg, L ^h   Chambers, J ⁱ   Kooner, J S ⁱ   Genest, J ^j   Rozen, R ^k   Ferrer Antunes, C ^l   Palmeiro, A ^l   Fernandez Arcas, N ^m   Reyes Engel, A ^m   Folsom, A R ⁿ   Fowkes, F G R ^o   Lee, A J ^o   Gemmati, D ^p   Scapoli, G L ^p   Girelli, D ^q   Corrocher, R ^q   Gulec, S ^r   Hopkins, P N ^s   Inbal, A ^t   Selighson, U ^t   Kluijtmans, L A J ^c   Jukema, J W ^u   Kozich, V ^v   Janosikova, B ^v   Ma, J ^w   Stampfer, M J ^w   Malinow, M R ^x   Ashfield Watt, P A L ^y   Clark, Z E ^y   Meisel, C ^z   Stangl, K ^z   Graham, I M ^aa   Morita, H ^ab   Nagai, R ^ac   Nakai, K ^ad   Yamakawa Kobayashi, K ^ae   Hamaguchi, H ^ae   Gaziano, M ^af   Schwartz, S M ^ag   Siscovick, D S ^ag   Silberberg, J S ^ah   Szczeklik, A ^ai   Domagala Teresa, B ^ai   Tanis, B C ^u   Rosendaal, F M ^u   Thogersen, A M ^aj   Nilsson, T K ^aj   Todesco, L ^ak   Litynsky, P ^al   Tokgozoglu, S L ^am   Tsai, M Y ^an   Hanson, N Q ^an   Rimm, E B ^ao   Verhoeff, B J ^ap   Trip, M D ^ap   more..

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF FLORENCE   (Italy)

^e GLENFIELD HOSPITAL   (United Kingdom)

^f UNIVERSITY OF UTAH   (United States)

^g Hemophilia and Thrombosis Center   (Italy)

^h ROYAL PERTH HOSPITAL   (Australia)

ⁱ NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^j ROYAL VICTORIA HOSPITAL   (Canada)

^k MONTREAL CHILDREN S HOSPITAL   (Canada)

^l CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^m UNIVERSIDAD DE MÁLAGA   (Spain)

ⁿ UNIVERSITY OF MINNESOTA   (United States)

^o UNIVERSITY OF EDINBURGH   (United Kingdom)

^p UNIVERSITY OF FERRARA   (Italy)

^q Policlinico G B Rossi   (Italy)

^r ANKARA UNIVERSITY   (Turkey)

^s Cardiovascular Genetics   (United States)

^t SHEBA MEDICAL CENTER   (Israel)

^u LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^v CHARLES UNIVERSITY   (Czech Republic)

^w CHANNING LABORATORY   (United States)

^x OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^y CARDIFF UNIVERSITY   (United Kingdom)

^z CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^aa ADELAIDE AND MEATH HOSPITAL   (Ireland)

^ab HARVARD MEDICAL SCHOOL   (United States)

^ac UNIVERSITY OF TOKYO   (Japan)

^ad IWATE MEDICAL UNIVERSITY   (Japan)

^ae UNIVERSITY OF TSUKUBA   (Japan)

^af BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ag Cardiovascular Health Research Unit   (United States)

^ah JOHN HUNTER HOSPITAL   (Australia)

^ai JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^aj UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^ak UNIVERSITY OF BASEL   (Switzerland)

^al UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^am HACETTEPE UNIVERSITY   (Turkey)

^an UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^ao HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ap ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASE;

AMINO ACID BLOOD LEVEL; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; CORONARY RISK; DNA POLYMORPHISM; EUROPE; FOLATE METABOLISM; FOLIC ACID BLOOD LEVEL; GENOTYPE; HUMAN; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; META ANALYSIS; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETICS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

CORONARY DISEASE; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037163849     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.16.2023     Document Type: Review

References (93)

1. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies. J Cardiovasc Risk. 1998; 5:229-232.
2. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr. 2000;72:315-323.
3. Verhoef P, Stampfer MJ, Rimm EB. Folate and coronary heart disease. Curr Opin Lipidol. 1998;9:17-22.
4. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204-210.
5. Voutilainen S, Lakka TA, Porkkala SE, Rissanen T, Kaplan GA, Salonen JT. Low serum folate concentrations are associated with an excess incidence of acute coronary events: The Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Clin Nutr. 2000;54:424-428.
6. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT. Low dietary folate intake is associated with an excess incidence of acute coronary events - The Kuopio Ischemic Heart Disease Risk Factor Study. Circulation. 2001;103:2674-2680.
7. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid. Clin Sci (Colch). 1999;96:235-239.
8. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation. 1998;98:2520-2526.
9. van der Put NM, Steegers-Theunissen R, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346: 1070-1071.
10. Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase: Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996;94: 3074-3078.
11. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
12. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997;96:412-417.
13. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening: The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation. 1999;99:2383-2388.
14. Kluijtmans LA, Kastelein JJ, Lindemans J, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease Circulation. 1997;96:2573-2577.
15. Blom HJ, Verhoef P. Hyperhomocysteinemia, MTHFR, and risk of vascular disease. Circulation. 2000; 101:E171.
16. Araujo F, Lopes M, Goncalves L, Maciel MJ, Cunha RL. Hyperhomocysteinemia, MTHFR C677T genotype and low folate levels: A risk combination for acute coronary disease in a Portuguese population. Thromb Haemost. 2000;83:517-518.
17. Chao CL, Tsai HH, Lee CM, et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999; 147:379-386.
18. Mager A, Lalezari S, Shohat T, et al. Methylenetetrahydrofolate reductase genotypes and earlyonset coronary artery disease. Circulation. 1999;100: 2406-2410.
19. Raslova K, Smolkova B, Vohnout B, Gasparovic J, Frohlich JJ. Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses: Comparison to controls without personal and family history of atherosclerosis. Metabolism. 2001;50:24-29.
20. Thuillier L, Chadefaux-Vekemans B, Bonnefont JP, et al. Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease? J Inherit Metab Dis. 1998;21:812-822.
21. Roest M, van der Schouw YT, Grobbee DE, et al. Methylenetetrahydrofolate reductase 677 C/T genotype and cardiovascular disease mortality in postmenopausal women. Am J Epidemiol. 2001;153:673-679.
22. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 1997;128:107-112.
23. Chen TY, Chen JH, Tsao CJ. Methylenetetrahydrofolate reductase gene polymorphism and coronary artery disease in Taiwan Chinese Haematologica. 2000;85:445-446.
24. Goracy I, Goracy J, Suliga M, Ciechanowicz A. Polimorfizm C677T genu reduktazy metylenotetrahydrofolianu (MTHFR) u chorych po przebytym zawale miesnia sercowego [C677T gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) in patients with myocardial infarction]. Pol Arch Med Wewn. 1999;102:849-854.
25. Hsu LA, Ko YL, Wang SM, et al. The C677T mutation of the methylenetetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered. 2001;51:41-45.
26. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis. 1996;121:293-294.
27. Kim CH, Hwang KY, Choi TM, Shin WY, Hong SY. The methylenetetrahydrofolate reductase gene polymorphism in Koreans with coronary artery disease. Int J Cardiol. 2001;78:13-17.
28. Kostulas K, Crisby M, Huang WX, et al. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invest. 1998;28:285-289.
29. Malik NM, Syrris P, Schwartzman R, et al. Methylenetetrahydrofolate reductase polymorphism (C-677T) and coronary artery disease. Clin Sci. 1998;95: 311-315.
30. Narang R, Callaghan G, Haider AW, Davies GJ, Tuddenham EG. Methylenetetrahydrofolate reductase mutation and coronary artery disease. Circulation. 1996;94:2322-2323.
31. Pinto X, Vilaseca MA, Garcia GN, et al. Homocysteine and the MTHFR 677C>T allele in premature coronary artery disease: Case control and family studies. Eur J Clin Invest. 2001;31:24-30.
32. Reinhardt D, Sigusch HH, Vogt SF, Farker K, Muller S, Hoffmann A. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest. 1998;28:20-23.
33. Wilcken DE, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol. 1996;16: 878-882.
34. Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol. 2000; 109:870-874.
35. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA. 1997; 277:1775-1781.
36. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst (e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
37. Silberberg JS, Crooks RL, Wlodarczyk JH, Fryer JL. Association between plasma folate and coronary disease independent of homocysteine. Am J Cardiol. 2001;87:1003-1004.
38. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345:1787-1793.
39. Meisel C, Cascorbi I, Gerloff T, et al. Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: Impact on plasma homocysteine levels and development of coronary artery disease. Atherosclerosis. 2001;154:651-658.
40. Abbate R, Sardi I, Pepe G, et al. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost. 1998;79:727-730.
41. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999;94:46-51.
42. Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Haematologica. 1999;84:824-828.
43. Girelli D, Friso S, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction. Blood. 1998;91:4158-4163.
44. Verhoef P, Kok FJ, Kluijtmans LA, et al. The 677C>T mutation in the methylenetetrahydrofolate reductase gene: Associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis. 1997;132:105-113.
45. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJ, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis. 1998;141: 161-166.
46. Szczeklik A, Sanak M, Jankowski M, et al. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet. 2001;101:36-39.
47. Ferrer AC, Palmeiro A, Morais J, Lourenco M, Freitas M, Providencia L. The mutation C677T in the methylene tetrahydrofolate reductase gene as a risk factor for myocardial infarction in the Portuguese population. Thromb Haemost. 1998;80:521-522.
48. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E, et al. The genotype interactions of methylenetetrahydrofolate reductase and renin-angiotensin system genes are associated with myocardial infarction. Atherosclerosis. 1999;145:293-300.
49. Thogersen AM, Nilsson TK, Dahlen G, et al. Homozygosity for the C677>T mutation of 5,10-methylenetetrahydrofolate reductase and total plasma homocyst(e) ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. Coron Artery Dis. 2001;12:85-90.
50. Todesco L, Angst C, Litynski P, Loehrer F, Fowler B, Haefeli WE. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest. 1999;29:1003-1009.
51. Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM. 1996;89:437-444.
52. Chambers JC, Ireland H, Thompson E, et al. Methylenetetrahydrofolate reductase 677 C>T mutation and coronary heart disease risk in UK Indian Asians. Arterioscler Thromb Vasc Biol. 2000;20:2448-2452.
53. Fowkes FG, Lee AJ, Hau CM, Cooke A, Connor JM, Lowe GD. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. Atherosclerosis. 2000;150:179-185.
54. McDowell IF, Clark ZE, Bowen DJ, Bellamy MF, Burr ML. Heteroduplex analysis for C677T genotyping of methylene tetrahydrofolate: A case-control study in men with angina. Neth J Med. 1998;52:S1-S61.
55. Christensen B, Frosst P, Lussier CS, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:569-573.
56. Anderson JL, King GJ, Thomson MJ, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 1997;30:1206-1211.
57. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 1997;17:1157-1162.
58. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: A case-control study. Circulation. 1996;94:1812-1814.
59. Tsai MY, Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis. 1999;143:163-170.
60. Verhoef P, Rimm EB, Hunter DJ, et al. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: Results among US men. J Am Coll Cardiol. 1998;32: 353-359.
61. van Bockxmeer F, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21-23
62. Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032-2036.
63. Nakai K, Fusazaki T, Suzuki T, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate increases risk of myocardial infarction and is correlated to elevated levels of homocysteine in the Japanese general population. Coron Artery Dis. 2000;11:47-51.
64. Ou T, Yamakawa-Kobayashi K, Arinami T, et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis. 1998;137:23-28.
65. Inbal A, Freimark D, Modan B, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood. 1999;93:2186-2190.
66. Gulec S, Aras O, Akar E, et al. Methylenetetrahydrofolate reductase gene polymorphism and risk of premature myocardial infarction. Clin Cardiol. 2001; 24:281-284.
67. Tokgozoglu SL, Alikasifoglu M, Unsal I, et al. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate: Heart. 1999;81:518-522.
68. Nomenclature and criteria for diagnosis of ischemic heart disease: Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Circulation. 1979;59:607-609.
69. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
70. Clark ZE, Bowen DJ, Whatley SD, Bellamy MF, Collins PW, McDowell FW. Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology. Clin Chem. 1998;44:2360-2362.
71. Kozich V, Janosikova B, Kylouskova M. Coronary Artery Disease (CAD) Study. Available at: http://www.lf1.cuni.cz/udmp/cad/. Accessed September 26, 2002.
72. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000;72:324-332.
73. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
74. Harmon DL, Woodside JV, Yarnell JW, et al. The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM. 1996;89:571-577.
75. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57:1098-1102.
76. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359-364.
77. Tucker KL, Selhub J, Wilson PW, Rosenberg IH. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr. 1996;126:3025-3031.
78. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham offspring cohort. Am J Clin Nutr. 2001;73:613-621.
79. Amorim-Cruz JA, Moreiras O, Brzozowska A. Longitudinal changes in the intake of vitamins and minerals of elderly Europeans. Eur J Clin Nutr. 1996;50 (suppl 2):S77-S85.
80. Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ. The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis. 2000;153: 161-168.
81. Refsum H, Ueland P, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med. 1998;49:31-62.
82. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363-375.
83. Gardemann A, Weidemann H, Philipp M, et al. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J. 1999; 20:584-592.
84. Lievers KJ, Boers GH, Verhoef P, et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med. 2001;79:522-528.
85. Heijmans BT, Gussekloo J, Kluft C, et al. Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR). Eur J Hum Genet. 1999;7:197-204.
86. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000;102:1227-1232.
87. Brattstrom L, Zhang Y, Hurtig M, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis. 1998;141:315-319.
88. Bladbjerg EM, Andersen RK, de Maat MP, et al. Longevity is independent of common variations in genes associated with cardiovascular risk. Thromb Haemost. 1999;82:1100-1105.
89. Hessner MJ, Dinauer DM, Kwiatkowski R, Neri B, Raife TJ. Age-dependent prevalence of vascular disease-associated polymorphisms among 2689 volunteer blood donors. Clin Chem. 2001;47:1879-1884.
90. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol. 2000;151:862-877.
91. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J Natl Cancer Inst. 2000;92:1151-1158.
92. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA. 2002;288:2015-2022.
93. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk. 1998;5: 249-255.